What Is Your Parkinson’s Clinical Research IQ?

1. A clinical research participant may discontinue participation in a study:

Whenever the individual wishes

Only if there are medical concerns

Only if the study is halted by the sponsor

Only with authorization from the individual’s physician

Something else to think about… when withdrawing from the trial, the participant should inform the research team and communicate the reasons for leaving the study.

Explanation

Something else to think about… when withdrawing from the trial, the participant should inform the research team and communicate the reasons for leaving the study.

2. The average time it takes for a drug to be developed and approved is:

Six months to one year

One to two years

Three to five years

10 to 15 years

The average time it takes for a drug to be developed and approved is 10 to 15 years. This is because the process of drug development involves several stages, including preclinical testing, clinical trials, regulatory review, and post-marketing surveillance. Each of these stages requires time for research, testing, analysis, and approval. Additionally, the drug development process also involves ensuring the safety and efficacy of the drug, which further contributes to the lengthy timeline.

Explanation

The average time it takes for a drug to be developed and approved is 10 to 15 years. This is because the process of drug development involves several stages, including preclinical testing, clinical trials, regulatory review, and post-marketing surveillance. Each of these stages requires time for research, testing, analysis, and approval. Additionally, the drug development process also involves ensuring the safety and efficacy of the drug, which further contributes to the lengthy timeline.

3. The percentage of clinical trials that are delayed at least one month because of the lack of clinical research participation is:

10 percent

40 percent

25 percent

80 percent

Something else to think about… The spending on participant recruitment in the U.S. increased from $275 million in 1998 to $500 million in 2002.

Explanation

Something else to think about… The spending on participant recruitment in the U.S. increased from $275 million in 1998 to $500 million in 2002.

4. The percentage of people with Parkinson’s who participate in clinical studies is estimated to be:

20 percent

10 percent

Five percent

One percent

Something else to think about… less than five percent of cancer patients participate in clinical trials. If 10 percent participated, studies could be completed in one year, instead of three to five years. (National Cancer Institute)

Explanation

Something else to think about… less than five percent of cancer patients participate in clinical trials. If 10 percent participated, studies could be completed in one year, instead of three to five years. (National Cancer Institute)

5. Most people with Parkinson’s learn about clinical studies through:

Their doctor

Support groups

The Internet

Other people with PD

Support groups are a common source of information for people with Parkinson's disease to learn about clinical studies. These groups provide a platform for individuals to share their experiences, knowledge, and resources related to Parkinson's disease. Support group members often discuss ongoing clinical trials, research studies, and new treatment options, which can help individuals stay informed about the latest advancements in Parkinson's research. Additionally, support groups offer emotional support, camaraderie, and a sense of community, making them an ideal setting for individuals to learn about and engage in clinical studies.

Explanation

Support groups are a common source of information for people with Parkinson's disease to learn about clinical studies. These groups provide a platform for individuals to share their experiences, knowledge, and resources related to Parkinson's disease. Support group members often discuss ongoing clinical trials, research studies, and new treatment options, which can help individuals stay informed about the latest advancements in Parkinson's research. Additionally, support groups offer emotional support, camaraderie, and a sense of community, making them an ideal setting for individuals to learn about and engage in clinical studies.